2024 World Conference on Lung Cancer (WCLC) - Posters-P1.01A.03 Can-Prevent-Lung Trial-Canakinumab for the Prevention of Lung Cancer: Updated Interim Clinical and Biomarker Analysis

P1.01A.03 Can-Prevent-Lung Trial-Canakinumab for the Prevention of Lung Cancer: Updated Interim Clinical and Biomarker Analysis

Back to course

Pdf Summary

The Can-Prevent-Lung Trial is a Phase II study investigating canakinumab, an anti-interleukin-1beta (IL-1B) antibody, for preventing lung cancer by increasing the regression rate of high-risk lung nodules. This trial builds on the CANTOS trial's findings, where canakinumab reduced lung cancer incidence by 70%. It focuses on patients with persistent high-risk lung nodules, defined as nodules not shrinking over at least two CT scans taken three months apart, with a 10-30% risk for those without a personal history of lung cancer, and 5-30% for those with a localized lung cancer history. If a nodule's risk score exceeds 30%, it must be biopsied to confirm the absence of malignancy.<br /><br />The updated interim analysis highlights canakinumab's favorable safety profile and its promising potential in treating high-risk nodules. Key adverse events documented include fatigue, decreased neutrophil and lymphocyte counts, hypercalcemia, increased creatinine levels, pain, diarrhea, limb edema, rash, and pruritus. Notably, two patients were removed from the study due to Grade 2 neutropenia, and adjustments in treatment cycles were made for others experiencing Grade 2 side effects.<br /><br />The study delves into the molecular and immune impact, showing that canakinumab treatment leads to the clearance of tumor DNA, confirmed by genomic aberration tests. Moreover, a rise in cytokines like ICOSL, IL-8, and MIG was observed post-treatment. The findings propose the utility of radiomics, molecular, and immune analysis in peripheral blood for lung cancer interception trials. <br /><br />For further inquiries, Dr. J. Zhang, associated with the MD Anderson Lung Cancer Interception Program, can be contacted via email.

Asset Subtitle

Jianjun Zhang

Meta Tag

Speaker Jianjun Zhang

Topic Risk Factors, Risk Reduction & Tobacco Control

Keywords

Can-Prevent-Lung Trial

canakinumab

lung cancer prevention

high-risk lung nodules

CANTOS trial

safety profile

tumor DNA clearance

cytokines

radiomics

MD Anderson